Developer docs
API playgroundTry for free, no card

Search company profiles

Simcere Pharma

Full company profile

uuid0004o2b

Namestring
Simcere Pharma
Legal namestring
Jiangsu Simcere Pharmaceutical Co., Ltd.
Websiteurl
simcere.com
Company typeenum
Public
Founded yearint
1995
Descriptiontext

Simcere Pharmaceutical Group (先声药业, 2096.HK) is a Nanjing-headquartered, innovation-driven Chinese pharmaceutical company founded in 1995 and listed on the Hong Kong Stock Exchange since 2020 (previously NYSE 2007-2013). The company operates across five therapeutic areas: oncology, neuroscience (CNS), autoimmune, cardiovascular and anti-infection, plus an "other fields" category, with 40+ commercial brands such as Endostar, Sanbexin, Bicun, Iremod, Orencia, Softan, Newanti, and a succession of newer launches (Enweida 2021, Cosela 2022, Xiannuoxin 2023, Enlituo 2024, Ke Weike and En Ze Shu 2025).

Underlying its commercial franchise is an R&D platform anchored by the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (Ministry of Science and Technology, 2015), the wholly owned oncology subsidiary Simcere Zaiming, and global R&D centers in Shanghai, Beijing, and Boston. The platform spans multi-specific antibodies (e.g., the TL1A x IL-23p19 bispecific SIM0709), antibody-drug conjugates (SIM0505 anti-CDH6, SIM0613 anti-LRRC15, plus the platform that produced the Ipsen-partnered preclinical ADC), small-molecule oncology (SIM0532 pan-RAS inhibitor, MAP2K-targeting coumarin compounds), and academic partnerships (Stanford Medicine for IPF first-in-class molecules). An in-house pipeline of 50+ innovative candidates is supplemented by in-licensed assets such as rademikibart (from Connect Biopharma) and zemprocitinib (from Lynk).

The business model combines direct domestic commercialization, out-licensing, and in-licensing. Hospital-focused field sales reach 1,900+ Class III hospitals and 17,000+ other Chinese medical institutions, supported by internal manufacturing in Hainan and Shandong. Globally, Simcere monetizes pipeline assets through upfront and milestone payments plus royalties, with the January 2026 Boehringer Ingelheim deal on SIM0709 worth €42M upfront and up to €1,016M in milestones, and a December 2025 $1B preclinical ADC deal with Ipsen serving as the marquee transactions. In-licensing is used to fill the China commercial funnel (Connect, Lynk, GI Innovation, Orencia/Sanbexin/Sanbexin sublingual type in-licensed assets). Disclosed 2025 revenue is approximately $1,105M, with 6,500+ staff across China, the U.S., and Singapore.

Short descriptiontext

Simcere Pharmaceutical Group (先声药业, 2096.HK) is a Nanjing-based, Hong Kong-listed Chinese pharma company founded in 1995 that develops, manufactures, and commercializes 40+ branded innovative and generic drugs across oncology, neuroscience, autoimmune, cardiovascular, and anti-infection therapeutic areas via hospital sales covering 1,900+ Class III hospitals in China, complemented by global out-licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersNanjing, China
HQ citystring
Nanjing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
innovative pharmaceuticals, oncology drug development, antibody-drug conjugates, prescription drug manufacturing, biopharmaceutical out-licensing
Industry4 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Branded Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical product sales
TypeHardware Sales
Description

Direct commercialization of 40+ branded prescription pharmaceutical products across oncology, neuroscience, autoimmune, cardiovascular/anti-infection, and other therapeutic areas via a hospital-focused sales network covering 1,900+ Class III hospitals and 17,000+ other institutions in China.

en.simcere.com
2Out-licensing of pipeline assets
TypeLicensing Royalties
Description

Licensing global (ex-Greater China) development and commercialization rights for pipeline assets to multinational pharma partners, generating upfront payments, milestone payments, and royalties. Example: SIM0709 deal with Boehringer Ingelheim (€42M upfront, up to €1,016M in milestones).

reuters.com
3In-licensing and co-promotion of partner assets
TypeLicensing Royalties
Description

Acquiring exclusive Greater China rights to third-party assets (e.g., rademikibart from Connect Biopharma, zemprocitinib from Lynk Pharmaceuticals) for development and commercialization in the China market, generating milestones and royalties to partners and product revenue domestically.

investing.com
4Strategic co-development partnerships
TypeLicensing Royalties
Description

Collaborative R&D agreements (e.g., with Stanford Medicine for first-in-class IPF molecule, with NextCure on CDH6 ADC) where Simcere funds research and acquires 100% of global rights upon success, generating long-term milestone and royalty streams.

pharmaceutical-technology.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1Enweida® (恩维达)
Description

Innovative drug approved in 2021

en.simcere.com
+7 more records
Core offering1 text field

Simcere Pharmaceutical Group is an innovation- and R&D-driven Chinese pharmaceutical company that develops, manufactures, and commercializes branded prescription pharmaceuticals across five therapeutic areas: Oncology, Neuroscience, Autoimmune, Cardiovascular/Anti-infection, and Other Fields. The company sells 40+ commercial brands directly to 1,900+ Class III hospitals and 17,000+ other medical institutions across China, and additionally monetizes its 50+ innovative pipeline candidates through out-licensing, co-development, and in-licensing partnerships with global biopharma (e.g., Boehringer Ingelheim, Ipsen, NextCure, Connect Biopharma, Lynk Pharmaceuticals, Stanford Medicine).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Sanbexin sublingual formulation: 64.4% of patients achieved modified Rankin Scale score of 1 or less at 90 days in Phase 3 trial, supporting breakthrough therapy designation.
+2 more records
Product overview1 text field

Simcere Pharma (先声药业, 2096.HK) operates a multi-brand pharmaceutical product portfolio organized into five therapeutic areas — Oncology, Neuroscience, Autoimmune, Cardiovascular & Anti-infection, and Other Fields — each comprising multiple commercial brand products. The Oncology portfolio includes Endostar®, Jepaso®, Jiebaili®, Sinofuan®, Enlength®, plus the innovative drugs Enweida® (2021) and Cosela® (2022). The Neuroscience portfolio is anchored by Sanbexin™ (including the sublingual edaravone-dexborneol tablet approved in 2025), Bicun®, and Ancozy®. The Autoimmune portfolio features Iremod®, Orencia® (approved 2020), and Yingtaiqing®. Cardiovascular & Anti-infection includes Softan®, OLMETEC PLUS®, ZAILIKE®, Newanti®, and ZAILIN®. The Other Fields portfolio contains Biqi®, Lowvo®, TB-PPD, KeChuanNing®, FANENG®, OUDIJIA®, and DINGAN®. More recent commercial launches include Xiannuoxin® (2023), Enlituo® (2024), Ke Weike® and En Ze Shu® (2025). On top of this commercial portfolio, Simcere operates an investigational pipeline through its subsidiary Simcere Zaiming, including oncology assets SIM0505 (CDH6 ADC), SIM0613 (anti-LRRC15 ADC), SIM0532 (pan-RAS inhibitor), a Stanford-partnered IPF program, the global-rights-out-licensed IBD bispecific SIM0709, co-developed immunology assets like rademikibart (with Connect Biopharma) and zemprocitinib/LNK01001 (with Lynk Pharmaceuticals). The company is supported by manufacturing bases, the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals, and global R&D centers in Shanghai and Boston.

Product and service16 records
1Enweida® (恩维达)
CategoryInnovative oncology drug (commercial)
Description

Simcere's innovative oncology drug approved and launched in 2021; included in the commercial pharmaceutical portfolio.

2Cosela® (科赛拉)
CategoryCommercial pharmaceutical product
Description

Simcere drug approved and launched in 2022 per company milestones timeline.

3Xiannuoxin® (先诺欣)
CategoryCommercial pharmaceutical product
Description

Simcere drug approved and launched in 2023 per company milestones timeline; received full approval in 2025 per Chinese site milestones.

4Enlituo® (恩立妥)
CategoryCommercial pharmaceutical product
Description

Simcere drug approved and launched in 2024 per the company milestones timeline.

5Ke Weike® (科唯可)
CategoryCommercial pharmaceutical product
Description

Simcere drug approved and launched in 2025 per Chinese site milestones timeline.

6En Ze Shu® (恩泽舒)
CategoryCommercial pharmaceutical product
Description

Simcere drug approved and launched in 2025 per Chinese site milestones timeline.

7Sanbexin® Sublingual Tablets (先必新® 舌下片, edaravone-dexborneol)
CategoryInnovative central nervous system drug (commercial)
Description

Sublingual tablet combining edaravone and dexborneol for acute ischemic stroke treatment; received China NMPA breakthrough therapy designation based on Phase 3 trial showing 64.4% of patients achieving mRS score ≤1 at 90 days. Approved and launched in sublingual tablet form in 2025.

8Sanbexin™ (先必新®) - core CNS brand
CategoryCommercial pharmaceutical product (Central Nervous System)
Description

Central nervous system product for stroke treatment; sublingual formulation combining edaravone and dexborneol received breakthrough therapy designation; the brand spans multiple formulations within Simcere's commercial neuroscience portfolio.

9Orencia®
CategoryCommercial pharmaceutical product (Autoimmune)
Description

Autoimmune brand product within Simcere's commercial autoimmune portfolio; approved in 2020 per company milestones.

10SIM0505 (CDH6-targeted ADC)
CategoryInvestigational oncology ADC (pipeline)
Description

Investigational antibody-drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a topoisomerase 1 inhibitor payload; being evaluated in Phase 1 for advanced solid tumors with emphasis on platinum-resistant ovarian cancer. Co-developed by Simcere Zaiming and NextCure.

11SIM0613 (anti-LRRC15 ADC)
CategoryInvestigational oncology ADC (pipeline)
Description

Anti-LRRC15 ADC independently developed by Simcere Zaiming; Phase I clinical trial initiated with first patient enrolled in China on June 2, 2026.

12SIM0532 (pan-RAS inhibitor)
CategoryInvestigational oncology small molecule (pipeline)
Description

Pan-RAS-targeted investigational anti-tumor drug independently developed by Simcere Zaiming; first patient dosed in clinical trial on May 21, 2026.

13SIM0709 (TL1A x IL-23p19 bispecific antibody)
CategoryInvestigational autoimmune bispecific antibody (out-licensed)
Description

Preclinical bispecific antibody for inflammatory bowel disease (IBD) that simultaneously targets TL1A and IL-23p19; demonstrated superior synergistic efficacy over corresponding monotherapies in preclinical cell and animal studies. Licensed to Boehringer Ingelheim for global (ex-Greater China) development and commercialization.

14Rademikibart (anti-IL-4Rα monoclonal antibody)
CategoryInvestigational autoimmune biologic (pipeline, in-licensed)
Description

Anti-IL-4Rα monoclonal antibody for atopic dermatitis, asthma, and COPD being co-developed with Connect Biopharma; Simcere holds Greater China rights via exclusive license with up to $110M in milestones plus tiered royalties. Phase 3 reported positive 52-week sustained efficacy and lower conjunctivitis rates versus Dupixent.

15Zemprocitinib (LNK01001, JAK inhibitor)
CategoryInvestigational autoimmune JAK inhibitor (pipeline, in-licensed)
Description

JAK inhibitor for rheumatoid arthritis developed by Lynk Pharmaceuticals; Simcere is the commercialization partner for Greater China. Phase III trial met all primary and key secondary efficacy endpoints with ACR20 response rate of 79.1% vs 39.7% at Week 24.

16First-in-Class IPF Molecule (Stanford Medicine collaboration)
CategoryInvestigational IPF therapy (research collaboration)
Description

First-in-class novel molecule for idiopathic pulmonary fibrosis (IPF) under joint research collaboration with Stanford Medicine's chemical biology laboratories led by professors Chaitan Khosla and Cui Bianxiao; Simcere funds the research and upon successful completion will license the molecule and obtain 100% of worldwide rights.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Chinese Polar Research Center (中国极地研究中心)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-07
Description

Deep cooperation agreement signed with Simcere on June 7, 2026 (Chinese-language source). Details of the partnership scope (R&D, healthcare for polar expeditions, etc.) referenced via Chinese website news page.

simcere.com
2Puqi Pharmaceutical (普祺医药)
Strategic tierModerateTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-01
Description

Exclusive promotion cooperation agreement for pumecitinib gel (announced June 1, 2026). Simcere Pharmaceutical Group (2096.HK) is the commercial counterparty in Greater China.

en.simcere.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-29
Description

Research collaboration agreement signed May 29, 2026 to jointly advance an exploratory study on idiopathic pulmonary fibrosis (IPF). Simcere will fund the exploratory research of a first-in-class novel molecule; upon successful completion, Simcere will in-license the molecule and obtain 100% of global rights to the resulting product. Conducted with Stanford's chemical biology laboratories led by Prof. Chaitan Khosla and Prof. Cui Bianxiao. Represents the second first-in-class original project worldwide between Simcere and Stanford Medicine and supports Simcere's Innovation 2.0 strategy.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-04
Description

Dose optimization portion of Phase 1 study initiated for SIM0505 in platinum-resistant ovarian cancer patients. Companies are expanding clinical trial sites into Canada and Europe in addition to the U.S. and China; Phase 1 data expected at ASCO 2026.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-04-23
Description

Exclusive license agreement granting Simcere rights to rademikibart for Greater China, worth up to $110 million in milestones plus tiered royalties. Simcere is running the China Phase 3 trial in moderate-to-severe atopic dermatitis (259 patients, sustained 52-week efficacy) with NDA pending and potential H2 approval triggering the milestone payments. Simcere also presented rademikibart Phase 3 AD data at AAD 2026.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Joint development of SIM0505, an antibody-drug conjugate targeting Cadherin-6 (CDH6) with a topoisomerase 1 inhibitor payload, for advanced solid tumors with an emphasis on platinum-resistant ovarian cancer. Phase 1 dose optimization initiated in May 2026; Phase 1 data accepted for poster presentation at ASCO 2026 (June 1, 2026). NextCure holds exclusive global rights outside of China, Hong Kong, Macau, and Taiwan; Simcere Zaiming retains rights within those territories. Clinical trial sites expanded into Canada and Europe in addition to the U.S. and China.

Strategic tierModerateTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

Collaboration in medical dermatology, including treatments for alopecia areata and atopic dermatitis, anchored by Almirall's new Shanghai innovation hub. Almirall is actively developing and commercializing dermatological treatments including a drug in Phase II trials for autoimmune diseases.

8Boehringer Ingelheim
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-27
Description

Exclusive global (ex-Greater China) licensing agreement for SIM0709, Simcere's preclinical bispecific antibody targeting TL1A and IL-23p19 for inflammatory bowel disease (IBD). Upfront payment of €42 million plus potential milestone payments up to an additional €1,016 million (~$1.27 billion). Demonstrated superior synergistic efficacy over corresponding monotherapies in preclinical studies. Simcere's second licensing transaction in the autoimmune field. Boehringer assumes global development and commercialization responsibility outside Greater China.

reuters.com
9Lynk Pharmaceuticals
Strategic tierModerateTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-12
Description

Commercialization partnership granting Lynk Pharmaceuticals rights to zemprocitinib (LNK01001) in Greater China. Positive Phase 3 topline results in 430 RA patients showed ACR20 of 79.1% vs 39.7% (placebo) at Week 24 (P < 0.0001). Lynk plans formal presentation at an upcoming international scientific conference.

prnewswire.com
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-11
Description

Technology transfer / licensing deal with China's Simcere valued at 1.146 trillion won for core pipelines (GI-301, GI-101, GI-102), one of multiple deals GI Innovation has signed with global pharma.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-23
Description

Ipsen announced a $1 billion investment in a Simcere preclinical antibody-drug conjugate (ADC) program. The deal emphasizes Ipsen's strategic focus on advanced biopharmaceuticals in Asia.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Hansoh Pharmaceutical
TypeDirect peer
Description

Leading Chinese innovative pharma listed in Hong Kong (3692.HK) with a comparable mix of branded generics plus a growing oncology and CNS innovative pipeline; directly comparable in therapeutic area focus, China hospital channel, and HKEX-listed status.

TypeDirect peer
Description

China-based biopharmaceutical company (1801.HK) developing innovative biologics including PD-1 antibodies and bispecifics; competes in the same oncology and autoimmune therapeutic areas and pursues similar out-licensing/strategic collaboration strategies with global pharma.

TypeDirect peer
Description

Global oncology-focused biopharma with deep China roots and a broad hematology/solid tumor pipeline; comparable as a Chinese-origin innovator pursuing both domestic commercialization and global development/licensing.

4Hutchmed (China MediTech)
TypeDirect peer
Description

Hong Kong-listed (13.HK) Chinese biopharma developing innovative oncology therapies with global out-licensing deals (e.g., AstraZeneca, Lilly); closely comparable in innovation model and out-licensing strategy from China.

TypeDirect peer
Description

Chinese biopharma (9926.HK) developing innovative antibodies including bispecifics (PD-1/VEGF, PD-1/CTLA-4); closely comparable in bispecific antibody focus and competitive oncology positioning.

TypeDirect peer
Description

Chinese biopharma (1877.HK, 688180.SH) with a leading PD-1 (toripalimab) and a deep pipeline of innovative biologics; comparable as a Chinese innovator pursuing global licensing/co-development (e.g., with Lilly and Coherus).

7Hengrui Pharmaceuticals
TypeBroad incumbent
Description

Largest innovative pharmaceutical company in China, listed on Shanghai Stock Exchange, with a broad pipeline across oncology, autoimmune, and other therapeutic areas; overlaps with Simcere's commercial areas but operates at much greater scale.

8Sino Biopharmaceutical
TypeBroad incumbent
Description

Large Chinese pharmaceutical conglomerate (1177.HK) with diversified branded generics and innovative drug businesses across oncology, hepatology, and respiratory; comparable in therapeutic breadth and HKEX-listed large-cap pharma positioning.

TypeBroad incumbent
Description

Major Hong Kong-listed Chinese pharma (1093.HK) with a sizable innovative drug and biosimilar portfolio spanning oncology, CNS, and anti-infection; comparable in therapeutic mix and HK-listed status.

TypeBroad incumbent
Description

Diversified Chinese healthcare group (2196.HK, 600196.SH) operating across pharma manufacturing, innovative R&D, and global distribution; comparable in international footprint (Boston office, cross-border licensing) and broad product portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment10 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Simcere Pharma

Branded Pharmaceuticalssimcere.com

Simcere Pharmaceutical Group (先声药业, 2096.HK) is a Nanjing-based, Hong Kong-listed Chinese pharma company founded in 1995 that develops, manufactures, and commercializes 40+ branded innovative and generic drugs across oncology, neuroscience, autoimmune, cardiovascular, and anti-infection therapeutic areas via hospital sales covering 1,900+ Class III hospitals in China, complemented by global out-licensing.

What Simcere Pharma does

Simcere Pharmaceutical Group (先声药业, 2096.HK) is a Nanjing-headquartered, innovation-driven Chinese pharmaceutical company founded in 1995 and listed on the Hong Kong Stock Exchange since 2020 (previously NYSE 2007-2013). The company operates across five therapeutic areas: oncology, neuroscience (CNS), autoimmune, cardiovascular and anti-infection, plus an "other fields" category, with 40+ commercial brands such as Endostar, Sanbexin, Bicun, Iremod, Orencia, Softan, Newanti, and a succession of newer launches (Enweida 2021, Cosela 2022, Xiannuoxin 2023, Enlituo 2024, Ke Weike and En Ze Shu 2025).

Underlying its commercial franchise is an R&D platform anchored by the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals (Ministry of Science and Technology, 2015), the wholly owned oncology subsidiary Simcere Zaiming, and global R&D centers in Shanghai, Beijing, and Boston. The platform spans multi-specific antibodies (e.g., the TL1A x IL-23p19 bispecific SIM0709), antibody-drug conjugates (SIM0505 anti-CDH6, SIM0613 anti-LRRC15, plus the platform that produced the Ipsen-partnered preclinical ADC), small-molecule oncology (SIM0532 pan-RAS inhibitor, MAP2K-targeting coumarin compounds), and academic partnerships (Stanford Medicine for IPF first-in-class molecules). An in-house pipeline of 50+ innovative candidates is supplemented by in-licensed assets such as rademikibart (from Connect Biopharma) and zemprocitinib (from Lynk).

The business model combines direct domestic commercialization, out-licensing, and in-licensing. Hospital-focused field sales reach 1,900+ Class III hospitals and 17,000+ other Chinese medical institutions, supported by internal manufacturing in Hainan and Shandong. Globally, Simcere monetizes pipeline assets through upfront and milestone payments plus royalties, with the January 2026 Boehringer Ingelheim deal on SIM0709 worth €42M upfront and up to €1,016M in milestones, and a December 2025 $1B preclinical ADC deal with Ipsen serving as the marquee transactions. In-licensing is used to fill the China commercial funnel (Connect, Lynk, GI Innovation, Orencia/Sanbexin/Sanbexin sublingual type in-licensed assets). Disclosed 2025 revenue is approximately $1,105M, with 6,500+ staff across China, the U.S., and Singapore.

Simcere Pharma firmographics

Firmographics
Name
Simcere Pharma
Legal name
Jiangsu Simcere Pharmaceutical Co., Ltd.
Website
https://simcere.com
Company type
Public
Founded year
1995
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Simcere Pharmaceutical Group (先声药业, 2096.HK) is a Nanjing-based, Hong Kong-listed Chinese pharma company founded in 1995 that develops, manufactures, and commercializes 40+ branded innovative and generic drugs across oncology, neuroscience, autoimmune, cardiovascular, and anti-infection therapeutic areas via hospital sales covering 1,900+ Class III hospitals in China, complemented by global out-licensing.
Ownership category
akta.pro rank

Simcere Pharma industry classification

Industry
Product category
Branded Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Innovative pharmaceuticals
  • Oncology drug development
  • Antibody-drug conjugates
  • Prescription drug manufacturing
  • Biopharmaceutical out-licensing

Where Simcere Pharma is headquartered

Location

Headquarters

HQ city
Nanjing
HQ country
China
HQ region
Asia

Offices6 records

Markets served

Simcere Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Pharmaceutical product sales: Direct commercialization of 40+ branded prescription pharmaceutical products across oncology, neuroscience, autoimmune, cardiovascular/anti-infection, and other therapeutic areas via a hospital-focused sales network covering 1,900+ Class III hospitals and 17,000+ other institutions in China.
  2. Out-licensing of pipeline assets: Licensing global (ex-Greater China) development and commercialization rights for pipeline assets to multinational pharma partners, generating upfront payments, milestone payments, and royalties. Example: SIM0709 deal with Boehringer Ingelheim (€42M upfront, up to €1,016M in milestones).
  3. In-licensing and co-promotion of partner assets: Acquiring exclusive Greater China rights to third-party assets (e.g., rademikibart from Connect Biopharma, zemprocitinib from Lynk Pharmaceuticals) for development and commercialization in the China market, generating milestones and royalties to partners and product revenue domestically.
  4. Strategic co-development partnerships: Collaborative R&D agreements (e.g., with Stanford Medicine for first-in-class IPF molecule, with NextCure on CDH6 ADC) where Simcere funds research and acquires 100% of global rights upon success, generating long-term milestone and royalty streams.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Simcere Pharma product offering

Product offering

Core offering

Simcere Pharmaceutical Group is an innovation- and R&D-driven Chinese pharmaceutical company that develops, manufactures, and commercializes branded prescription pharmaceuticals across five therapeutic areas: Oncology, Neuroscience, Autoimmune, Cardiovascular/Anti-infection, and Other Fields. The company sells 40+ commercial brands directly to 1,900+ Class III hospitals and 17,000+ other medical institutions across China, and additionally monetizes its 50+ innovative pipeline candidates through out-licensing, co-development, and in-licensing partnerships with global biopharma (e.g., Boehringer Ingelheim, Ipsen, NextCure, Connect Biopharma, Lynk Pharmaceuticals, Stanford Medicine).

Product overview

Simcere Pharma (先声药业, 2096.HK) operates a multi-brand pharmaceutical product portfolio organized into five therapeutic areas — Oncology, Neuroscience, Autoimmune, Cardiovascular & Anti-infection, and Other Fields — each comprising multiple commercial brand products. The Oncology portfolio includes Endostar®, Jepaso®, Jiebaili®, Sinofuan®, Enlength®, plus the innovative drugs Enweida® (2021) and Cosela® (2022). The Neuroscience portfolio is anchored by Sanbexin™ (including the sublingual edaravone-dexborneol tablet approved in 2025), Bicun®, and Ancozy®. The Autoimmune portfolio features Iremod®, Orencia® (approved 2020), and Yingtaiqing®. Cardiovascular & Anti-infection includes Softan®, OLMETEC PLUS®, ZAILIKE®, Newanti®, and ZAILIN®. The Other Fields portfolio contains Biqi®, Lowvo®, TB-PPD, KeChuanNing®, FANENG®, OUDIJIA®, and DINGAN®. More recent commercial launches include Xiannuoxin® (2023), Enlituo® (2024), Ke Weike® and En Ze Shu® (2025). On top of this commercial portfolio, Simcere operates an investigational pipeline through its subsidiary Simcere Zaiming, including oncology assets SIM0505 (CDH6 ADC), SIM0613 (anti-LRRC15 ADC), SIM0532 (pan-RAS inhibitor), a Stanford-partnered IPF program, the global-rights-out-licensed IBD bispecific SIM0709, co-developed immunology assets like rademikibart (with Connect Biopharma) and zemprocitinib/LNK01001 (with Lynk Pharmaceuticals). The company is supported by manufacturing bases, the National Key Laboratory of Translational Medicine and Innovative Pharmaceuticals, and global R&D centers in Shanghai and Boston.

Differentiator

Problem solved

Functional benefit

Brands

  • Enweida® (恩维达): Innovative drug approved in 2021
  • Cosela® (科赛拉)
  • Xiannuoxin® (先诺欣)
  • Enlituo® (恩立妥)
  • Ke Weike® (科唯可)
  • Enzeshu® (恩泽舒)
  • Sanbexin® (先必新)
  • Simcere Zaiming (先声再明)

Products and services

  • Enweida® (恩维达) Simcere's innovative oncology drug approved and launched in 2021; included in the commercial pharmaceutical portfolio.
  • Cosela® (科赛拉) Simcere drug approved and launched in 2022 per company milestones timeline.
  • Xiannuoxin® (先诺欣) Simcere drug approved and launched in 2023 per company milestones timeline; received full approval in 2025 per Chinese site milestones.
  • Enlituo® (恩立妥) Simcere drug approved and launched in 2024 per the company milestones timeline.
  • Ke Weike® (科唯可) Simcere drug approved and launched in 2025 per Chinese site milestones timeline.
  • En Ze Shu® (恩泽舒) Simcere drug approved and launched in 2025 per Chinese site milestones timeline.
  • Sanbexin® Sublingual Tablets (先必新® 舌下片, edaravone-dexborneol) Sublingual tablet combining edaravone and dexborneol for acute ischemic stroke treatment; received China NMPA breakthrough therapy designation based on Phase 3 trial showing 64.4% of patients achieving mRS score ≤1 at 90 days. Approved and launched in sublingual tablet form in 2025.
  • Sanbexin™ (先必新®) - core CNS brand Central nervous system product for stroke treatment; sublingual formulation combining edaravone and dexborneol received breakthrough therapy designation; the brand spans multiple formulations within Simcere's commercial neuroscience portfolio.
  • Orencia® Autoimmune brand product within Simcere's commercial autoimmune portfolio; approved in 2020 per company milestones.
  • SIM0505 (CDH6-targeted ADC) Investigational antibody-drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a topoisomerase 1 inhibitor payload; being evaluated in Phase 1 for advanced solid tumors with emphasis on platinum-resistant ovarian cancer. Co-developed by Simcere Zaiming and NextCure.
  • SIM0613 (anti-LRRC15 ADC) Anti-LRRC15 ADC independently developed by Simcere Zaiming; Phase I clinical trial initiated with first patient enrolled in China on June 2, 2026.
  • SIM0532 (pan-RAS inhibitor) Pan-RAS-targeted investigational anti-tumor drug independently developed by Simcere Zaiming; first patient dosed in clinical trial on May 21, 2026.
  • SIM0709 (TL1A x IL-23p19 bispecific antibody) Preclinical bispecific antibody for inflammatory bowel disease (IBD) that simultaneously targets TL1A and IL-23p19; demonstrated superior synergistic efficacy over corresponding monotherapies in preclinical cell and animal studies. Licensed to Boehringer Ingelheim for global (ex-Greater China) development and commercialization.
  • Rademikibart (anti-IL-4Rα monoclonal antibody) Anti-IL-4Rα monoclonal antibody for atopic dermatitis, asthma, and COPD being co-developed with Connect Biopharma; Simcere holds Greater China rights via exclusive license with up to $110M in milestones plus tiered royalties. Phase 3 reported positive 52-week sustained efficacy and lower conjunctivitis rates versus Dupixent.
  • Zemprocitinib (LNK01001, JAK inhibitor) JAK inhibitor for rheumatoid arthritis developed by Lynk Pharmaceuticals; Simcere is the commercialization partner for Greater China. Phase III trial met all primary and key secondary efficacy endpoints with ACR20 response rate of 79.1% vs 39.7% at Week 24.
  • First-in-Class IPF Molecule (Stanford Medicine collaboration) First-in-class novel molecule for idiopathic pulmonary fibrosis (IPF) under joint research collaboration with Stanford Medicine's chemical biology laboratories led by professors Chaitan Khosla and Cui Bianxiao; Simcere funds the research and upon successful completion will license the molecule and obtain 100% of worldwide rights.

Quantifiable outcome

  • Sanbexin sublingual formulation: 64.4% of patients achieved modified Rankin Scale score of 1 or less at 90 days in Phase 3 trial, supporting breakthrough therapy designation.
  • +2 more outcomes

Companies that use Simcere Pharma

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Simcere Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Simcere Pharma partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered minor, moderate, flagship and major.

  • Chinese Polar Research Center (中国极地研究中心)minorStrategic or Co-development Partner · 7 June 2026Deep cooperation agreement signed with Simcere on June 7, 2026 (Chinese-language source). Details of the partnership scope (R&D, healthcare for polar expeditions, etc.) referenced via Chinese website news page.
  • Puqi Pharmaceutical (普祺医药)moderateChannel Partner/ Reseller/ Distributor · 1 June 2026Exclusive promotion cooperation agreement for pumecitinib gel (announced June 1, 2026). Simcere Pharmaceutical Group (2096.HK) is the commercial counterparty in Greater China.
  • Stanford MedicineflagshipStrategic or Co-development Partner · 29 May 2026Research collaboration agreement signed May 29, 2026 to jointly advance an exploratory study on idiopathic pulmonary fibrosis (IPF). Simcere will fund the exploratory research of a first-in-class novel molecule; upon successful completion, Simcere will in-license the molecule and obtain 100% of global rights to the resulting product. Conducted with Stanford's chemical biology laboratories led by Prof. Chaitan Khosla and Prof. Cui Bianxiao. Represents the second first-in-class original project worldwide between Simcere and Stanford Medicine and supports Simcere's Innovation 2.0 strategy.
  • NextCure, Inc. (SIM0505 expansion)majorStrategic or Co-development Partner · 4 May 2026Dose optimization portion of Phase 1 study initiated for SIM0505 in platinum-resistant ovarian cancer patients. Companies are expanding clinical trial sites into Canada and Europe in addition to the U.S. and China; Phase 1 data expected at ASCO 2026.
  • Connect Biopharma Holdings LimitedmajorOEM/ Whitelabel/ Licensing Partner · 23 April 2026Exclusive license agreement granting Simcere rights to rademikibart for Greater China, worth up to $110 million in milestones plus tiered royalties. Simcere is running the China Phase 3 trial in moderate-to-severe atopic dermatitis (259 patients, sustained 52-week efficacy) with NDA pending and potential H2 approval triggering the milestone payments. Simcere also presented rademikibart Phase 3 AD data at AAD 2026.
  • NextCure, Inc.majorStrategic or Co-development Partner · 21 April 2026Joint development of SIM0505, an antibody-drug conjugate targeting Cadherin-6 (CDH6) with a topoisomerase 1 inhibitor payload, for advanced solid tumors with an emphasis on platinum-resistant ovarian cancer. Phase 1 dose optimization initiated in May 2026; Phase 1 data accepted for poster presentation at ASCO 2026 (June 1, 2026). NextCure holds exclusive global rights outside of China, Hong Kong, Macau, and Taiwan; Simcere Zaiming retains rights within those territories. Clinical trial sites expanded into Canada and Europe in addition to the U.S. and China.
  • AlmirallmoderateStrategic or Co-development Partner · 19 March 2026Collaboration in medical dermatology, including treatments for alopecia areata and atopic dermatitis, anchored by Almirall's new Shanghai innovation hub. Almirall is actively developing and commercializing dermatological treatments including a drug in Phase II trials for autoimmune diseases.
  • Boehringer IngelheimflagshipOEM/ Whitelabel/ Licensing Partner · 27 January 2026Exclusive global (ex-Greater China) licensing agreement for SIM0709, Simcere's preclinical bispecific antibody targeting TL1A and IL-23p19 for inflammatory bowel disease (IBD). Upfront payment of €42 million plus potential milestone payments up to an additional €1,016 million (~$1.27 billion). Demonstrated superior synergistic efficacy over corresponding monotherapies in preclinical studies. Simcere's second licensing transaction in the autoimmune field. Boehringer assumes global development and commercialization responsibility outside Greater China.
  • Lynk PharmaceuticalsmoderateOEM/ Whitelabel/ Licensing Partner · 12 January 2026Commercialization partnership granting Lynk Pharmaceuticals rights to zemprocitinib (LNK01001) in Greater China. Positive Phase 3 topline results in 430 RA patients showed ACR20 of 79.1% vs 39.7% (placebo) at Week 24 (P < 0.0001). Lynk plans formal presentation at an upcoming international scientific conference.
  • GI InnovationminorOEM/ Whitelabel/ Licensing Partner · 11 January 2026Technology transfer / licensing deal with China's Simcere valued at 1.146 trillion won for core pipelines (GI-301, GI-101, GI-102), one of multiple deals GI Innovation has signed with global pharma.
  • IpsenflagshipOEM/ Whitelabel/ Licensing Partner · 23 December 2025Ipsen announced a $1 billion investment in a Simcere preclinical antibody-drug conjugate (ADC) program. The deal emphasizes Ipsen's strategic focus on advanced biopharmaceuticals in Asia.

Scale indicators8 records

Recent moves12 records

Expansion highlights6 records

Simcere Pharma competitors and assessment

Company assessment

Direct peers

  • Hansoh Pharmaceutical: Leading Chinese innovative pharma listed in Hong Kong (3692.HK) with a comparable mix of branded generics plus a growing oncology and CNS innovative pipeline; directly comparable in therapeutic area focus, China hospital channel, and HKEX-listed status.
  • Innovent Biologics: China-based biopharmaceutical company (1801.HK) developing innovative biologics including PD-1 antibodies and bispecifics; competes in the same oncology and autoimmune therapeutic areas and pursues similar out-licensing/strategic collaboration strategies with global pharma.
  • BeiGene (now BeOne Medicines): Global oncology-focused biopharma with deep China roots and a broad hematology/solid tumor pipeline; comparable as a Chinese-origin innovator pursuing both domestic commercialization and global development/licensing.
  • Hutchmed (China MediTech): Hong Kong-listed (13.HK) Chinese biopharma developing innovative oncology therapies with global out-licensing deals (e.g., AstraZeneca, Lilly); closely comparable in innovation model and out-licensing strategy from China.
  • Akeso: Chinese biopharma (9926.HK) developing innovative antibodies including bispecifics (PD-1/VEGF, PD-1/CTLA-4); closely comparable in bispecific antibody focus and competitive oncology positioning.
  • Junshi Biosciences: Chinese biopharma (1877.HK, 688180.SH) with a leading PD-1 (toripalimab) and a deep pipeline of innovative biologics; comparable as a Chinese innovator pursuing global licensing/co-development (e.g., with Lilly and Coherus).

Broad incumbents

  • Hengrui Pharmaceuticals: Largest innovative pharmaceutical company in China, listed on Shanghai Stock Exchange, with a broad pipeline across oncology, autoimmune, and other therapeutic areas; overlaps with Simcere's commercial areas but operates at much greater scale.
  • Sino Biopharmaceutical: Large Chinese pharmaceutical conglomerate (1177.HK) with diversified branded generics and innovative drug businesses across oncology, hepatology, and respiratory; comparable in therapeutic breadth and HKEX-listed large-cap pharma positioning.
  • CSPC Pharmaceutical Group: Major Hong Kong-listed Chinese pharma (1093.HK) with a sizable innovative drug and biosimilar portfolio spanning oncology, CNS, and anti-infection; comparable in therapeutic mix and HK-listed status.
  • Fosun Pharma: Diversified Chinese healthcare group (2196.HK, 600196.SH) operating across pharma manufacturing, innovative R&D, and global distribution; comparable in international footprint (Boston office, cross-border licensing) and broad product portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Simcere Pharma social profiles

Digital presence

Simcere Pharma compliance and trust

Trust signal

Compliance3 records

Simcere Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Simcere Pharma leadership team

Management profile

Number of profiles

Profiles10 records

Simcere Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Simcere Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Simcere Pharma M&A and investment

M&A and investment

M&A

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Simcere Pharma

What does Simcere Pharma do?

Simcere Pharmaceutical Group is an innovation- and R&D-driven Chinese pharmaceutical company that develops, manufactures, and commercializes branded prescription pharmaceuticals across five therapeutic areas: Oncology, Neuroscience, Autoimmune, Cardiovascular/Anti-infection, and Other Fields. The company sells 40+ commercial brands directly to 1,900+ Class III hospitals and 17,000+ other medical institutions across China, and additionally monetizes its 50+ innovative pipeline candidates through out-licensing, co-development, and in-licensing partnerships with global biopharma (e.g., Boehringer Ingelheim, Ipsen, NextCure, Connect Biopharma, Lynk Pharmaceuticals, Stanford Medicine).

Is Simcere Pharma a public or private company?

Simcere Pharma is a public company. It is classified as public and is currently operating.

When was Simcere Pharma founded?

Simcere Pharma was founded in 1995. It employs 5,001 to 10,000 people.

Where is Simcere Pharma based?

Simcere Pharma is headquartered in Nanjing, China, in the Asia region.

How does Simcere Pharma make money?

Four revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are out-licensing of pipeline assets, in-licensing and co-promotion of partner assets and strategic co-development partnerships.

Who are Simcere Pharma's main competitors?

Direct peers on record are Hansoh Pharmaceutical, Innovent Biologics, BeiGene (now BeOne Medicines), Hutchmed (China MediTech), Akeso and Junshi Biosciences. Broad incumbents are Hengrui Pharmaceuticals, Sino Biopharmaceutical, CSPC Pharmaceutical Group and Fosun Pharma.

Does Simcere Pharma have an API?

No public API is recorded for Simcere Pharma.

What industry is Simcere Pharma in?

Simcere Pharma's product category is Branded Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechCash-strapped Vivoryon regains China rights to kidney disease prospect from SimcereVivoryon Therapeutics regained China rights to its kidney disease prospect varoglutamstat from Simcere Pharmaceuticals, returning rights and agreeing to make milestone payments if approved. The Munich-based biotech, with cash reserves of 1.7 million euros, is seeking new funding or partners for a phase 2b trial.BioSpaceBoehringer bets big on China, offering $7B biobucks for Sino cancer programsBoehringer Ingelheim signed a deal with Sino Biopharmaceutical to develop six preclinical cancer programs, paying $358 million upfront and up to $7 billion in milestones and royalties. The partnership, Boehringer's second oncology collaboration with Sino, follows the opening of a Shanghai R&D center. Boehringer also recently committed $1.26 billion to Simcere Pharmaceutical for an IBD asset.pharmaphorumRoche taps Simcere for autoimmune trispecific for $1.53bnRoche agreed to pay $75 million for a trispecific antibody SIM0660 from Simcere Zaiming, with the deal potentially reaching $1.53 billion including milestones. The antibody targets CD79a, CD19, and CD3 and is in preclinical development. Simcere's sixth out-licensing deal is part of its $6.1 billion portfolio.Investing.comWhy is Simcere Pharmaceutical stock surging today? By Investing.comSimcere Pharmaceutical's stock surged 7.5% to HK$11.81 after its oncology subsidiary announced an exclusive global licensing deal with Roche for SIM0660. The deal includes a $75 million upfront payment and up to $1.455 billion in milestones, bringing total potential value to over $6.1 billion.Investing.comWhy is Simcere Pharmaceutical stock surging today? By Investing.comSimcere Pharmaceutical shares rose 7.5% to HK$11.81 after its oncology subsidiary announced an exclusive global licensing deal with Roche for SIM0660. The agreement could pay up to $1.53 billion, including a $75 million upfront and tiered royalties. Analysts rate the stock a Buy with a HK$16.30 target.MarketScreenerRoche, Simcere Pharma Strike Drug Licensing DealRoche agreed to pay Simcere Pharma $75 million upfront for exclusive global rights to develop, manufacture, and commercialize SIM0660, an antibody targeting B-cell malignancies. Simcere is eligible for up to $1.455 billion in milestone payments and tiered royalties on future net sales.European BiotechnologyRoche reloads B-cell strategy with $1.53B Simcere dealRoche acquired exclusive worldwide rights to Simcere's SIM0660, a CD79axCD19xCD3 bispecific, for $1.53 billion plus tiered royalties. The deal aims to deepen B-cell depletion in blood cancers and autoimmune diseases, following Roche's discontinuation of a lupus T-cell engager.PR Newswire APACSimcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global DevelopmentSimcere Zaiming entered an exclusive global licensing agreement with Roche for SIM0660, a tri-specific antibody targeting CD79a, CD19, and CD3. Roche will acquire exclusive rights, with Simcere eligible for up to $1.530 billion, including $75 million upfront and tiered royalties. The deal follows six prior out-licensing transactions totaling over $6.1 billion.PR NewswireSimcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global DevelopmentSimcere Zaiming entered an exclusive global licensing agreement with Roche for SIM0660, a tri-specific antibody targeting CD79a, CD19, and CD3. Roche will acquire exclusive rights, with Simcere eligible for up to $1.530 billion, including $75 million upfront and tiered royalties. The deal follows six prior out-licensing transactions totaling over $6.1 billion.Bamboo WorksPrimeGenX looks to a Hong Kong IPO as a cure for its cash woesPrimeGenX Therapeutics has applied for a second time to list on the Hong Kong Stock Exchange to address severe cash flow constraints after withdrawing previous plans for a Beijing listing. The biotech firm, which is currently loss-making with net liabilities, has licensed out commercialization rights for its key products to Jumpcan Pharmaceutical and Jiangsu Simcere Pharmaceutical to generate upfront capital.